Literature DB >> 24421545

Ado-trastuzumab emtansine and radium 223 dichloride.

Dominic A Solimando, J Aubrey Waddell.   

Abstract

The complexity of cancer chemotherapy requires pharmacists be familiar with the complicated regimens and highly toxic agents used. This column reviews various issues related to preparation, dispensing, and administration of antineoplastic therapy, and the agents, both commercially available and investigational, used to treat malignant diseases. Questions or suggestions for topics should be addressed to Dominic A. Solimando, Jr., President, Oncology Pharmacy Services, Inc., 4201 Wilson Blvd #110-545, Arlington, VA 22203, email: OncRxSvc@comcast.net; or J. Aubrey Waddell, Professor, University of Tennessee College of Pharmacy; Oncology Pharmacist, Pharmacy Department, Blount Memorial Hospital, 907 E. Lamar Alexander Parkway, Maryville, TN 37804, e -mail: waddfour@charter.net.

Entities:  

Year:  2013        PMID： 24421545      PMCID： PMC3857123          DOI： 10.1310/hpj4809-729

Source DB:  PubMed          Journal:  Hosp Pharm        ISSN： 0018-5787


  19 in total

1.  A phase 1 study of weekly dosing of trastuzumab emtansine (T-DM1) in patients with advanced human epidermal growth factor 2-positive breast cancer.

Authors:  Muralidhar Beeram; Ian E Krop; Howard A Burris; Sandhya R Girish; Wei Yu; Michael W Lu; Scott N Holden; Shanu Modi
Journal:  Cancer       Date:  2012-05-30       Impact factor: 6.860

2.  A phase II study of trastuzumab emtansine in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer who were previously treated with trastuzumab, lapatinib, an anthracycline, a taxane, and capecitabine.

Authors:  Ian E Krop; Patricia LoRusso; Kathy D Miller; Shanu Modi; Denise Yardley; Gladys Rodriguez; Ellie Guardino; Michael Lu; Maoxia Zheng; Sandhya Girish; Lukas Amler; Eric P Winer; Hope S Rugo
Journal:  J Clin Oncol       Date:  2012-05-29       Impact factor: 44.544

Review 3.  Radioimmunotherapy with alpha-emitting nuclides.

Authors:  M R McDevitt; G Sgouros; R D Finn; J L Humm; J G Jurcic; S M Larson; D A Scheinberg
Journal:  Eur J Nucl Med       Date:  1998-09

Review 4.  High-linear energy transfer irradiation targeted to skeletal metastases by the alpha-emitter 223Ra: adjuvant or alternative to conventional modalities?

Authors:  Øyvind S Bruland; Sten Nilsson; Darrell R Fisher; Roy H Larsen
Journal:  Clin Cancer Res       Date:  2006-10-15       Impact factor: 12.531

Review 5.  A randomized, dose-response, multicenter phase II study of radium-223 chloride for the palliation of painful bone metastases in patients with castration-resistant prostate cancer.

Authors:  S Nilsson; P Strang; A K Aksnes; L Franzèn; P Olivier; A Pecking; J Staffurth; S Vasanthan; C Andersson; Ø S Bruland
Journal:  Eur J Cancer       Date:  2012-02-15       Impact factor: 9.162

6.  Trastuzumab emtansine for HER2-positive advanced breast cancer.

Authors:  Sunil Verma; David Miles; Luca Gianni; Ian E Krop; Manfred Welslau; José Baselga; Mark Pegram; Do-Youn Oh; Véronique Diéras; Ellie Guardino; Liang Fang; Michael W Lu; Steven Olsen; Kim Blackwell
Journal:  N Engl J Med       Date:  2012-10-01       Impact factor: 91.245

7.  Significant antitumor effect from bone-seeking, alpha-particle-emitting (223)Ra demonstrated in an experimental skeletal metastases model.

Authors:  Gjermund Henriksen; Knut Breistøl; Øyvind S Bruland; Øystein Fodstad; Roy H Larsen
Journal:  Cancer Res       Date:  2002-06-01       Impact factor: 12.701

8.  First clinical experience with alpha-emitting radium-223 in the treatment of skeletal metastases.

Authors:  Sten Nilsson; Roy H Larsen; Sophie D Fosså; Lise Balteskard; Kari W Borch; Jan-Erik Westlin; Gro Salberg; Oyvind S Bruland
Journal:  Clin Cancer Res       Date:  2005-06-15       Impact factor: 12.531

9.  Phase I study of trastuzumab-DM1, an HER2 antibody-drug conjugate, given every 3 weeks to patients with HER2-positive metastatic breast cancer.

Authors:  Ian E Krop; Muralidhar Beeram; Shanu Modi; Suzanne F Jones; Scott N Holden; Wei Yu; Sandhya Girish; Jay Tibbitts; Joo-Hee Yi; Mark X Sliwkowski; Fred Jacobson; Stuart G Lutzker; Howard A Burris
Journal:  J Clin Oncol       Date:  2010-04-26       Impact factor: 44.544

10.  Clinical pharmacology of trastuzumab emtansine (T-DM1): an antibody-drug conjugate in development for the treatment of HER2-positive cancer.

Authors:  Sandhya Girish; Manish Gupta; Bei Wang; Dan Lu; Ian E Krop; Charles L Vogel; Howard A Burris Iii; Patricia M LoRusso; Joo-Hee Yi; Ola Saad; Barbara Tong; Yu-Waye Chu; Scott Holden; Amita Joshi
Journal:  Cancer Chemother Pharmacol       Date:  2012-01-20       Impact factor: 3.333
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.